

| 카탈로그 번호 | HV974226 |
|---|---|
| 설명 |
Davoceticept (HV974226) is a research-grade recombinant antibody targeting CD1. Produced in mammalian cells with native-like glycosylation.
Highlights
|
| 종 반응성 | Human |
| 응용 분야 | ELISA, Functional assay, Research in vivo |
| 이소타입 | Fusion - [CD80 (B7-1, CD28LG1) fragment (1-107)]2 - IGHG1 Fc (Fragment constant) |
| 발현 시스템 | Mammalian Cells |
| 타겟 | B7-H1, Programmed cell death 1 ligand 1, PDCD1 ligand 1, PDCD1L1, B7 homolog 1, PDCD1LG1, PDL1, hPD-L1, Programmed death ligand 1, B7H1, PD-L1, CD274, CD28, TP44, T-cell-specific surface glycoprotein CD28, CD152, Cytotoxic T-lymphocyte protein 4, CTLA-4, CTLA4, Cytotoxic T-lymphocyte-associated antigen 4 |
| 내독소 수준 | Please contact the lab for this information. |
| 순도 | >95% purity as determined by SDS-PAGE. |
| 정제 | Protein A/G purified from cell culture supernatant. |
| 등록번호 | Q9NZQ7 & P10747 & P16410 |
| 형태 | Liquid |
| 저장 완충액 | 0.01M PBS, pH 7.4. 데이터시트 인쇄본 또는 로트별 COA에 기재된 구체적인 완충액 정보를 참조하세요. |
| 안정성 및 저장 | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| 대체 이름 | ALPN-202, CD80vIgD-Fc, 2307144-64-3 |
| 배경 | Davoceticept (ALPN-202; CD80 vIgD-Fc) is a variant CD80 vIgD-Fc fusion protein targeting CTLA-4 and PD-L1. Davoceticept consists of the (1-107) fragment of CD80 linked to IGHG1 Fc via a peptidyl linker. The expression system of Davoceticept is usually CHO (Chinese Hamster Ovary) cells. |
| 참고사항 | For research use only. Not suitable for clinical or therapeutic use. |

SDS-PAGE for Research Grade Davoceticept


+86-027-65523339
중국 우한시 심둔사로 666번지 C동, 우한, 430206

中文
English
한국어
日本語
Español
Français
Русский